Table 2.

Effect of alogliptin on the carotid plaque according to the level of baseline GSM

	n	Mean change (SE) of alogliptin treatment group	n	Mean change (SE) of conventional treatment group	Adj. mean difference (95% CI)	p value between groups
Right GSM-plaque
First tertile
52 weeks	5	20.6 (5.2)**	14	6.6 (3.1)*	14.1 (1.3, 26.8)	0.03
104 weeks		26.4 (4.6)**		10.9 (2.9)**	15.6 (3.9, 27.2)	0.01
Second tertile
52 weeks	10	0.1 (4.2)	11	− 0.1 (4.0)	0.1 (− 12.1, 12.3)	0.99
104 weeks		0.3 (3.1)		− 3.1 (3.0)	3.4 (− 5.6, 12.4)	0.44
Third tertile
52 weeks	8	− 5.2 (4.7)	10	− 8.8 (4.2)	3.6 (− 9.8, 17.0)	0.57
104 weeks		− 9.2 (4.2)*		− 6.6 (3.5)	− 2.6 (− 14.4, 9.2)	0.65
Left GSM-plaque
First tertile
52 weeks	11	18.0 (4.0)**	14	21.2 (3.6)**	− 3.2 (− 14.5, 8.0)	0.56
104 weeks		17.1 (4.6)**		19.1 (4.1)**	− 2.0 (− 14.7, 10.8)	0.75
Second tertile
52 weeks	11	− 0.4 (3.5)	12	1.5 (3.3)	− 1.9 (− 11.9, 8.1)	0.69
104 weeks		0.9 (4.0)		3.5 (3.7)	− 2.7 (− 14.0, 8.7)	0.63
Third tertile
52 weeks	13	− 10.6 (4.1)*	11	− 6.4 (4.5)	− 4.2 (− 18.0, 9.6)	0.53
104 weeks		− 2.1 (5.3)		− 7.6 (5.7)	5.5 (− 11.5, 22.4)	0.51

Data are mean (SE) unless otherwise stated. Comparisons of GSMs during treatment with those at baseline were performed with one-sample t test based on a mixed-effects model for repeated measures. Differences in Δchange in GSM from baseline at 52 and 104 weeks between groups were analyzed with a mixed-effects model for repeated measures. Treatment group, week, interactions between treatment group and week, and baseline GSM were included as fixed effects

*p < 0.05; ** p < 0.01